BIO-TECHNE Corp Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
BIO-TECHNE Corp (TECH) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $35.40 million as of 2018-07-01, per its 10-K/A filed 2019-11-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2019-11-06
- 2018-07-01: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $35.40M.
- 2018-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $35.40M.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2018-07-01 | $35.40M 10-K/A · filed 2019-11-06 |
| 2018-06-30 | $35.40M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |